HARMONY GOLD MNG-SPON ADR (HMY)       4.01  -0.09 (-2.2%)

4.01  -0.09 (-2.2%)

US4132163001 - ADR - After market: 4 -0.01 (-0.25%)


Fundamental Rating

3

Taking everything into account, HMY scores 3 out of 10 in our fundamental rating. HMY was compared to 969 industry peers in the Metals & Mining industry. The financial health of HMY is medium. Also its profitability is quite bad. HMY is not valued too expensively and it also shows a decent growth rate.

Note: HMY has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

HMY has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of HMY.

VS Industry

Valuation

Valuation Rating

4

With a Forward Price/Earnings Ratio of 10.40, the valuation of HMY can be described as very reasonable.
HMY's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
When comparing the current price to the book value of HMY, we can conclude it is valued correctly. It is trading at 1.50 times its book value.

Compared to an average industry price book ratio of 1.68, HMY is valued in line with its industry peers.
When comparing the Enterprise Value to EBITDA ratio of HMY to the average industry ratio of 6.23, HMY is valued in line with its industry peers.
HMY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
VS Industry

Price/Book (1.5) VS Industry: 52% outperformed.

6,836.00
0.03

Enterprise Value/ EBITDA (6.14) VS Industry: 51% outperformed.

374.61
0.07

Growth

Growth Rating

5

The Earnings Per Share is expected to grow by 23.33% on average over the next 5 years. This is a very strong growth
The Revenue has been growing by 17.23% on average over the past 5 years. This is quite good.
HMY shows a small growth in Revenue. In the last year, the Revenue has grown by 2.19%.

HMY is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 2.52% yearly.
HMY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -127.62%.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -127.62% 22.92% 31.35% 23.33% N/A
Revenue17.23% 16.58% 2.19% 5.58% 7.66% 2.52% N/A

Health

Health Rating

4

HMY has a Current Ratio of 1.51. This is a normal value and indicates that HMY is financially healthy and should not expect problems in meeting its short term obligations.
HMY has one of the worst Debt to Equity ratios in its industry. 80% of its industry peers require less debt for financing their operations.
Although this is true, HMY has a very low Debt to Equity (0.11). So we won't put much weight on the industry comparison.
HMY has an Altman-Z score of 2.70. This is not the best score and indicates that HMY is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score is in line with the industry averages, which is at 2.51.

Compared to an average industry Current Ratio of 2.56, HMY is worse placed to pay its short term obligations than its industry peers.
HMY has a Quick Ratio of 1.51. This is a bad value and indicates that HMY is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Quick Ratio of HMY to the average industry Current Ratio of 2.16, HMY is less able to pay its short term obligations than its industry peers.
The Piotroski-F score of HMY is 3.00. This is a low score and indicates issues in the health and profitability of HMY.
VS Industry

Debt/Equity (0.11) VS Industry: 20% outperformed.

4.14
0.00

Quick Ratio (0.94) VS Industry: 27% outperformed.

0.00
178.59

Current Ratio (1.51) VS Industry: 32% outperformed.

0.00
178.59

Altman-Z (2.7) VS Industry: 50% outperformed.

-22,403.48
2,514.55

Dividend

Dividend Rating

2

HMY has paid a dividend for at least 10 years, which is a reliable track record.
HMY has a yearly dividend return of 0.84%, which is pretty low.
With a Dividend Yield of 0.84, HMY pays less dividend than the industry average, which is at 2.10. 91% of the companies listed in the same industry pay a better dividend than HMY!

With a Dividend Yield of 0.84, HMY pays less dividend than the S&P500 average, which is at 2.60.
The earnings of HMY are negative and hence is the payout ratio. HMY will probably not be able to sustain this dividend level.
VS Industry

Dividend Yield (0.84%) VS Industry: 9% outperformed.

0.27
24.74

HARMONY GOLD MNG-SPON ADR4.01

NYSE:HMY (3/29/2023, 7:12:13 PM)-0.09 (-2.2%)

After market: 4 -0.01 (-0.25%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)03-01 2023-03-01
Earnings (Next)N/A N/A
Inst Owners29.29%
Inst Owner Change-7.23%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.48B
Analysts45.71
Price Target3.21 (-19.95%)
Dividend
Industry RankSector Rank
Dividend Yield 0.84%
Dividend Growth(5Y)N/A
DP-40.87%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)0.52%
PT rev (3m)8.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.22%
EPS NY rev (3m)0.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.89%
Revenue NY rev (3m)1.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.4
P/S 1.06
P/FCF 63.44
P/OCF 6.51
P/B 1.5
P/tB 1.5
EV/EBITDA 6.14
EPS(TTM)-0.09
EYN/A
EPS(NY)0.39
Fwd EY9.62%
FCF(TTM)0.06
FCFY1.58%
OCF(TTM)0.62
OCFY15.37%
SpS3.8
BVpS2.67
TBVpS2.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC 7.7%
ROICexc 8.18%
ROICexgc 8.19%
OM 9.41%
PM N/A
GM 12.15%
ROICexgc(3y)9.12%
ROICexcg growth 3Y41.23%
ROICexcg growth 5Y41.64%
ROICexc(3y)9.04%
ROICexc growth 3Y41.95%
ROICexc growth 5Y42.11%
OM growth 3Y29.8%
OM growth 5Y25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.42%
GM growth 5Y10.56%
F-Score3
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 5.14
Debt/EBITDA 0.47
Cap/Depr 168.72%
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 0.94
Altman-Z 2.7
F-Score3
WACC17.25%
ROIC/WACC0.47
Cap/Depr(3y)134.75%
Cap/Depr(5y)141.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-127.62%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-247.78%
EPS Next Y22.92%
EPS Next 2Y31.35%
EPS Next 3Y23.33%
EPS Next 5YN/A
Revenue growth 1Y2.19%
Revenue growth 3Y16.58%
Revenue growth 5Y17.23%
Revenue growth Q2Q2.73%
Revenue Next Year5.58%
Revenue Next 2Y7.66%
Revenue Next 3Y2.52%
Revenue Next 5YN/A
EBIT growth 1Y-35.53%
EBIT growth 3Y51.33%
EBIT growth 5Y46.53%
EBIT Next Year115.54%
EBIT Next 3Y35.14%
EBIT Next 5YN/A
FCF growth 1Y-82.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.57%
OCF growth 3Y13.96%
OCF growth 5Y12.73%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA